HR positive + HER-2 negative

Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)

Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)

The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)

Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)

Watch Dr. Jennifer Litton discuss treatment recommendations and supporting research on use of endocrine therapy and CDK4/6 inhibitors for both metastatic and high-risk, early HR positive/HER2 negative breast cancer. https://t.co/b2WPpFRNbp @MDEdgeTweets @JenniferLitton #EndCancer (@MDAndersonNews)

New📰in Current Treatment Options in Oncology from Dr. Erica Mayers and Dr. Jamie Brett discussing new developments in systemic management for high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer. @elmayermd #breastcancer 👉https://t.co/kJMnlxuaxX (@DFCI_BreastOnc)

also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)

In this #OpenAccess review, @laura_huppert et al discuss current and emerging therapies for both early-stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data 🔗 https://t.co/TS4avPLsog @Idossa_MD @hoperugo (@CAonline)

Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial https://t.co/1qdrIoP8b8 So proud to be part of this! TKI is a very promising, low cost biomarker! (@FilippoMontemu1)

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial https://t.co/EbRGcGlZVr (@MLPOncoData)

Be sure to read the full article here! Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE) #BrownJC https://t.co/7CicovKBIW (@DrSGraff)

At an @theNCI town hall with staff this morning, I shared that I’ve been very recently diagnosed with hormone receptor-positive, HER2-negative early #BreastCancer. My prognosis is very favorable. To anyone with cancer today: I am truly in this together with you. #bcsm (@NCIDirector)

It is a pleasure to share with you the poster LACOG 0221 - BRAVE - Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil, presented in the @SABCSSanAntonio in Texas, USA, by Dr. @GWerutsky (@LACOG_group)

A CDK4/6 inhibitor plus endocrine therapy combination extended PFS by nearly a year compared with #chemotherapy as first-line treatment for premenopausal patients with aggressive, HR-positive/HER2-negative advanced #breastcancer. #SABCS22. https://t.co/06hfUVhUI7 @VKaklamani (@MedpageOnco)

.@YAbdouMD and colleagues reported at #SABCS22 that Non-Hispanic Black women with hormone receptor (HR)-positive/HER2-negative, lymph node-positive breast cancer had worse outcomes compared to non-Hispanic whites, Asians, and Hispanics. https://t.co/YYBy4EKu2f (@UNC_Lineberger)

Black women with hormone receptor-positive/HER2-negative breast cancer may have worse outcomes than their peers despite similar genetic risk scores, according to a new analysis of the RxPONDER trial presented at #SABCS22. Learn more: https://t.co/p7Fa9ImYqW @YAbdouMD (@AACR)

Something to watch out amidst surge of Abema. (wishing it away since retro analysis..remember, a case report led to id of pandemic) Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Re… https://t.co/3cl2LQtI5Z (@iBreastSurgeon)

P5-02-31 Thursday @SABCSSanAntonio Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial Presenter: @fara_bm (@prat_aleix)

P1-13-16Tuesday @SABCSSanAntonio Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer Presenter: @fara_bm (@prat_aleix)

P3-06-02 Wednesday @SABCSSanAntonio TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis Presenter: @Prat2Prat2022 ()

LISTEN: @hoperugo @UCSFHospitals on the latest results from the TROPiCS-02 trial showing Trodelvy improves overall survival compared to chemotherapy in metastatic, hormone receptor-positive, HER2-negative breast cancer. https://t.co/aOjC27RsWV via @Breastcancerorg #bcsm (@UCSFCancer)

DARE study #bcsm DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer - Full Text View - https://t.co/WcqCirJpp7 (@maryam_lustberg)

Trodelvy significantly improved overall survival for patients with HR-positive/HER2 negative #metastaticbreastcancer who are endocrine therapy-resistant, a population with limited treatment options, explained @hoperugo from @UCSFCancer at #ESMO22. #BCSM https://t.co/FroXdAGvub (@cure_today)

Dr Stephen Johnston provides past 12 months new data for hormone receptor positive HER2 negative metastatic breast cancer at #ESMO22 (@teamoncology)

Trodelvy demonstrated a clinically meaningful improvement of 3.2 monthin overall survival compared to physician choice chemotherapy. A new treatment choice for hormone receptor-positive HER2 negative metastatic breast cancer. Exciring. https://t.co/LAzeObZBD2 (@teamoncology)

Up next is Dr. Tufia Haddad with updates on hormone receptor positive and HER2-negative breast cancer. Man, there is a lot of exciting stuff going on in breast cancer therapy these days! I have such respect for oncologists in general practice. There is so much data out there… 😮 (@OncoThor)

CDK4/6 inhibition + endocrine therapy extends post-progression PFS in HR-positive/HER2-negative metastatic #BreastCancer. https://t.co/mgm853Emiu @KalinskyKevin @claudine_isaacs @LombardiCancer @WinshipAtEmory #ASCO22 #ASCODailyNews #BCSM (@ASCO)

15.8 months improved OS 1st line for premenopausal #HR #bcsm patients w/ the addition of ribociclib Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer - The ASCO Post https://t.co/KteUaTVvOr (@ErikaHamilton9)

After a bumpy start, CDK4/6 inhibitors have started to gain traction in early hormone receptor (HR)-positive/HER2-negative breast cancer, reported @stolaney1, MD, at #miamibreast. By @CBankheadMPT @gotoPER https://t.co/hPZ9juhM7P (@MedpageOnco)

"Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS @FUCAMM @OncoAlert @BCTrials (@Dr_Ivanoncologo)

Michael Gnant on HR-Positive HER2-Negative Early Breast Cancer Trial Results With Palbociclib Treatment - The ASCO Post https://t.co/WdlHwzMSdX @ABCSGVienna @elmayermd @AngieDemichele (@MichaelGnant)

Lisa A. Carey, MD, on HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies https://t.co/MVhx0Jj54k #bcsm #SABCS21 #oncology #cancer @DrLisaCarey @UNC_Lineberger (@ASCOPost)

Particularly, in the hormone receptor positive/HER2 negative breast cancer subtype. Among Black women, they had almost double the recurrence risk of white women. This is consistent from earlier reports in the @folopade research team. (@tigerlilycares)

Happening at 11AM in Hall 3: Dr. Gradishar & @BCJoyceO: Study of samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer. #SABCS21 #oncology #SABCS2021 (@IDEOOncology)

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a @FDAOncology pooled analysis https://t.co/PNFGTQlQCc #bcsm @OncoAlert (@aftimosp)

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine https://t.co/fuawAaSfVj (@VivekSubbiah)

Congratulations to @mfrimawi for publishing his research on the management of hormone receptor-positive, HER2-negative #MetastaticBreastCancer in the Breast Cancer Research and Treatment Journal. #Oncology #OncTwitter @StLukesHealthMD @BCMCancerCenter https://t.co/wdvhJNtF25 (@ProfAMThompson)

🚨⭐️Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor + fulvestrant: @FDAOncology pooled analysis #BCSM @drjennifergao https://t.co/Lr5r3ZFwMy (@VivekSubbiah)

🚨@myESMO daily reporter outlines CDK4/6 inhibitors & MONALEESA trial by @MDAndersonNews legend Dr. Hortobagyi that has led to a paradigm shift in the treatment of HR-positive/HER2-negative #aBC, @OncoAlert #ESMO21 Editorial by @CarmenCriscit 👉 https://t.co/yn0I19kChC #bcsm (@VivekSubbiah)

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial https://t.co/0Wwh5q1RcO (@VivekSubbiah)

News: Phase 2 data reported by @stolaney1 (@DanaFarber) and colleagues in @JAMAOnc do not support the addition of #pembrolizumab to #eribulin for HR-positive, HER2-negative metastatic #BreastCancer #bcsm https://t.co/J78O1jsjcs (@MM_Oncology)

#ESMO20 news: Combining #palbociclib with adjuvant endocrine therapy did not benefit HR-positive, HER2-negative, early #BreastCancer patients in the #PALLAS trial presented by @elmayermd (@danafarber) at #ESMO2020 #BCSM https://t.co/I6XXc4sj1f (@MM_Oncology)